Posts Tagged ‘Patrick Bedford’

Trying to get it right: a blog carnival about Right to Try

Author: Stacey Johnson, 08/29/17

The crux of Right to Try legislation, enacted by 37 U.S. states so far, is the premise that terminally ill patients should have access to experimental therapies, even if they haven’t been approved by the Food and Drug Administration yet. It sounds straight-forward right? My body, my risk, my decision. The U.S. already has measures…Read more

Weighing in on a controversial topic

Author: Stacey Johnson, 08/23/17

We are less than one week away from Signals’ second blog carnival! Last month I promised to reveal the topic and the participants. I also hinted that this year’s topic might strike some readers as controversial. Given that a few invited bloggers declined to participate, I’d have to say that’s the case. So although our…Read more

Right Turn: Primers on cell therapy regulation

Author: Stacey Johnson, 06/16/17

Understanding cell therapy regulation is an essential component of the bench to bedside pipeline. Without approval from a country’s regulator (Health Canada, FDA, EMA, PMDA, etc.), a product cannot be sold to consumers and the millions invested in research and development, manufacturing and clinical trials is media down the drain. Cell therapies present a range…Read more

Right Turn: Stem cell researchers develop more than undifferentiated stem cells at StemCellTalks Toronto

Author: Erin Sugar, 03/24/17

The eighth annual Toronto StemCellTalks (SCT) symposium took place on March 10, 2017, in Toronto’s urban innovation hub (and CCRM’s new home), MaRS Discovery District. SCT is a national stem cell biology outreach program for high school students in partnership with Let’s Talk Science and the Stem Cell Network. (CCRM is also a proud national…Read more